GLOBAL BLOOD THERAPEUTICS IN (GBT)
US37890U1088 - Common Stock
ChartMill assigns a Buy % Consensus number of 68% to GBT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 67.97. This target is -0.77% below the current price.
GBT was analyzed by 22 analysts. The buy percentage consensus is at 68. So analysts seem to be have mildly positive about GBT.
In the last month the buy percentage fell by 15 points. So the trust of analysts is decreasing.
GBT was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-09 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-08-09 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-08-09 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-08-09 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-08-09 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2022-08-08 | Stifel | Downgrade | Buy -> Hold |
| 2022-08-08 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-08-08 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2022-08-08 | Jefferies | Downgrade | Buy -> Hold |
| 2022-06-28 | JP Morgan | Maintains | Neutral |
| 2022-05-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-02-24 | Oppenheimer | Maintains | Outperform |
| 2021-12-21 | SVB Leerink | Maintains | Outperform |
| 2021-12-14 | SVB Leerink | Maintains | Outperform |
| 2021-12-07 | William Blair | Upgrade | Market Perform -> Outperform |
| 2021-11-05 | RBC Capital | Maintains | Outperform |
| 2021-10-07 | Jefferies | Initiate | Buy |
| 2021-08-04 | Truist Securities | Upgrade | Hold -> Buy |
| 2021-06-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-05-06 | Roth Capital | Maintains | Buy |
| 2021-05-06 | Canaccord Genuity | Maintains | Hold |
| 2021-04-14 | SVB Leerink | Initiate | Outperform |
| 2021-03-12 | Wolfe Research | Initiate | Outperform |